Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424446 | 1.00 | ESR2 (0.50) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL12385989 | 1.00 | ESR2 (0.50) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28232795 | 0.97 | ESR2 (0.48) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL13924884 | 0.85 | — | — | |
| SCHEMBL17706160 | 0.79 | KDM4E (0.34) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL3012888 | 0.79 | KDM4E (0.34) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL17835264 | 0.79 | KDM4E (0.34) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL13523771 | 0.77 | KDM4E (0.33) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL25568146 | 0.77 | KDM4E (0.37) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL898237 | 0.76 | KDM4E (0.44) | KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107787315-A | (1S, 3S, 4R) 4 ((3AS, 4R, 5S, 7AS) 4 (aminomethyl) 7A methyl, 1 methylene octahydro 1H indenes, 5 base) 3 (methylol) 4 methyl cyclohexanol acetate crystalline solid forms | 阿奎诺克斯药物（加拿大）公司 | 2018-03-09 | — | — | CN | claimed |
| EP-2970100-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | claimed |
| EP-2970122-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | claimed |
| WO-2014158654-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-10-02 | — | — | WO | claimed |
| WO-2014143561-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-09-18 | — | — | WO | claimed |
| CN-105209429-B | SHIP1 conditioning agents and relative method | 阿奎诺克斯药物（加拿大）公司 | 2018-05-29 | — | — | CN | disclosed |
| US-20170158703-A9 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20160194331-A1 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-2970100-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014143561-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| EP-2185537-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194331-A1 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | ESR2 1997/4885KDM4E 4371/4885PKM 1380/4885 |
| US-20170158703-A9 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | ESR2 1997/4885KDM4E 4371/4885PKM 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.